Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for VivoSim Labs, Inc. (VIVS : NSDQ)

• Company Description    VivoSim Labs Inc. is a clinical-stage biotechnology company. It involved in developing drugs which are demonstrated to be effective in three-dimensional human tissues as candidates for drug development. The company focuses on developing novel treatment approaches in inflammatory bowel disease. VivoSim Labs Inc., formerly known as Organovo Holdings Inc., is based in SAN DIEGO, United States. Number of Employees: 13

• Price / Volume Information    Yesterday's Closing Price: $2.00 Daily Weekly Monthly 20 Day Moving Average: 4,894,789 shares Shares Outstanding: 2.61 (millions) Market Capitalization: $5.22 (millions) Beta: 1.21 52 Week High: $21.96 52 Week Low: $1.41 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -4.31% -2.85% 12 Week -7.83% -10.98% Year To Date 10.50% 10.65%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11555 SORRENTO VALLEY ROAD SUITE 100 - SAN DIEGO,CA 92121 USA ph: 858-224-1000 fax: - info@vivosim.ai http://www.vivosim.ai

• General Corporate Information    Officers Keith Murphy - Executive Chairman Norman Staskey - Chief Financial Officer Adam Stern - Director Douglas Cohen - Director David Gobel - Director Peer Information VivoSim Labs, Inc. (CORR.) VivoSim Labs, Inc. (RSPI) VivoSim Labs, Inc. (CGXP) VivoSim Labs, Inc. (BGEN) VivoSim Labs, Inc. (GTBP) VivoSim Labs, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 68620A302 SIC: 2836 Fiscal Year Fiscal Year End: March Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/18/26 Share - Related Items Shares Outstanding: 2.61 Most Recent Split Date: 3.00 (0.08:1) Beta: 1.21 Market Capitalization: $5.22 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/18/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.17 Price/Cash Flow: - Price / Sales: 36.73 EPS Growth vs. Year Ago Period: 41.69% vs. Previous Quarter: 14.04% Sales Growth vs. Year Ago Period: 8.33% vs. Previous Quarter: -7.14% ROE 12/31/25 - -15.51 09/30/25 - -28.83 06/30/25 - -32.95 ROA 12/31/25 - -11.31 09/30/25 - -19.71 06/30/25 - -21.31 Current Ratio 12/31/25 - 2.44 09/30/25 - 3.10 06/30/25 - 4.52 Quick Ratio 12/31/25 - 2.44 09/30/25 - 3.10 06/30/25 - 4.52 Operating Margin 12/31/25 - -861.27 09/30/25 - -1,413.57 06/30/25 - -1,396.48 Net Margin 12/31/25 - -861.27 09/30/25 - -1,413.57 06/30/25 - -1,396.48 Pre-Tax Margin 12/31/25 - -862.68 09/30/25 - -1,415.00 06/30/25 - -1,399.30 Book Value 12/31/25 - 1.70 09/30/25 - 2.71 06/30/25 - 3.67 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - 0.02 Debt-to-Equity 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©